Pulmonary cavitation – an under-recognized late complication of severe COVID-19 lung disease

MATERIALS AND METHODS

A registry of all patients admitted to our institution with COVID-19, and approved by the institution’s Research Ethics Committee, was retrospectively reviewed. In total 689 patients were admitted between February 23^rd and July 3^rd 2020, of whom 330 had asymptomatic or mild disease, 359 had evidence of pneumonia and 110 were admitted to Intensive Care for treatment of respiratory failure. One hundred and seventy eight patients had CT scans of the chest and all patients who had cavitary lung disease on CT scan were identified. Baseline demographics, comorbidities, symptoms, ventilatory and other Intensive care parameters, microbiology, medications received and hospital outcomes were reviewed. Data was extracted by one of three members of the research team, and verified by a second researcher. All CT scans were reviewed by a single thoracic radiologist and imaging characteristics were noted.

In the absence of approved pharmacologic therapy for COVID-19, the Department of Infectious Diseases and the antimicrobial stewardship program at our institution rapidly developed institutional practice guidelines for COVID-19 based on available in-vitro and clinical studies to aid clinicians with treatment decisions. These guidelines were frequently updated based on emerging data. In the early stages of the pandemic asymptomatic and symptomatic patients were treated with a combination of two or three medications that included hydroxychloroquine, lopinavir-ritonavir and favipiravir, for a duration of 5-10 days. Tocilizumab was recommended for those with evolving cytokine release storm (CRS) based on criteria that encompassed clinical, radiological and laboratory parameters. One dose was initially given and a second dose was optional based on the clinical evolution of the patient. Empiric antibacterial and antifungal treatment was not routinely administered unless there was clinical suspicion for secondary pneumonia. Amoxicillin-clavulanate and piperacillin-tazobactam were the most common antibiotics used for COVID-19 patients.

RESULTS

Twelve patients with COVID-19 disease developed lung cavitation, comprising 1.7% (n = 12/689) of all admissions, 3.3% (n = 12/359) of those with COVID-19 pneumonia, and 11% (n = 12/110) of those admitted to the ICU. Table 1 describes their baseline characteristics, clinical variables and outcomes. Median (range) age was 47 (37 to 67) years, 50% (n = 6/12) had diabetes mellitus, 42% (n = 5/12) were hypertensive and one had chronic lung disease in the form of chronic obstructive pulmonary disease (COPD). None had received prior immunosuppression. All 12 were males, required invasive mechanical ventilation, and the median (range) time from symptom onset to invasive mechanical ventilation was 8 (3-15) days. Three were admitted directly via our institution’s Emergency Department and intubated within 24 hours, whilst the other nine patients were transferred from other hospitals within 72 hours of intubation. At the time of this data review six of the 12 patients had died, another remains critically ill and unlikely to survive, one is still admitted having been recently decannulated off extra-corporeal membrane oxygenation (ECMO) and had his tracheostomy decannulated, and four have been discharged home.

Most patients had completed a course of Hydroxychloroquine (83 % n = 10/12) and antivirals (favipilavir or lopinavir/ritonavir) (92%, n = 11/12) in the early stages of their illness. All 12 patients received Tocilizumab as clinical evidence of a CRS became apparent accompanied by deteriorating respiratory status and progressively worsening disease on imaging. Overall, this represented 9% (n=12/133) of patients with COVID-19 who received tocilizumab in our institution.

DISCUSSION

The development of pulmonary cavitation in patients with severe COVID-19 lung disease treated in our institution’s ICU was not a rare event (11%, n = 12/110). This subgroup of patients had very severe infection with acute respiratory distress syndrome (ARDS) and required a prolonged ICU stay. Median (range) Sequential Organ Failure Assessment (SOFA) score was 23 (range 16-24) on admission, and all patients were leucopenic. Seven of 12 required renal replacement therapy, four developed venous thromboembolism, three required ECMO with two surviving to successful decannulation, and two had thromboembolic cerebrovascular events.

Cavities tended to form in areas of the lung where ground glass opacities where seen in early stages, morphing into more dense consolidation, later developing necrosis and ultimately cavitating. This is demonstrated for patients 8 and 9 in Figures 1 and 2, respectively. We are unable to speculate as to whether bacterial infection and/or invasive fungal coinfection may have contributed to the development of the cavities, or if the infections were opportunistic. However it is uncommon for viral pneumonias,[8] including those due to the other human coronaviruses SARS-CoV[9] and MERS-CoV,[10] to cause pulmonary cavitation even in severe and advanced viral infection. Furthermore, four of twelve patients who had developed pulmonary cavitation (including two of the survivors) had no microbiological, serological, clinical or distinct radiological characteristics of invasive fungal infection and did not receive treatment for this.

• Download figure
• Open in new tab

Fig. 1

Axial and coronal CT images at form patient 8 on (A) 5^th May 2020, (B) 26^th May 2020, and (C) 6^th June 2020.

• Download figure
• Open in new tab

Fig. 2

Axial and coronal CT images at form patient 9 on (A) 14^th May 2020, (B) 8^th June 2020, and (C) 18^th June 2020.

Four patients developed hemoptysis and all had features of suspected invasive aspergillosis. Hemoptysis appeared to have occurred irrespective of cavity size. Similarly, secondary pneumothorax also occurred in patients with both larger and smaller cavities.

All patients in this series received tocilizumab, a recombinant humanized monoclonal antibody directed against both the soluble and membrane-bound forms of the interleukin-6 (IL-6) receptor, in the early stages of a CRS. Tocilizumab is currently approved by the US Food and Drug Administration (FDA) for the treatment of severe rheumatoid arthritis, systemic juvenile idiopathic arthritis, giant cell arteritis, and life-threatening CRS induced by chimeric antigen receptor T cell therapy[11]. Recently it has been associated with improved survival in patients with severe COVID-19 pneumonia with evidence of CRS.[12,13] In general tocilizumab is well tolerated but can induce neutropenia, and an increased risk of developing infections has been reported.[14,15] Furthermore, it may predispose to a delay in detecting active infection because of the masking effect of a suppressed C reactive protein (CRP) response. Interestingly, however, only one of 12 patients in our cohort developed neutropenia during their ICU stay.

All patients in this series also received systemic glucocorticoids, which may have survival benefit in COVID-19[16], but also suppress the immune system by impairing innate immunity. In the treatment of patients reported here systemic steroids were administered as part of our ICU protocol for septic shock, based on the Society of Critical Care Medicine guidelines[17] and not directly for the treatment of their COVID-19.

The high level of morbidity and mortality in this small case series highlights that cavity formation probably sits at the severe/end-stage of the radiological COVID-19 spectrum. It is unclear what the natural history of these cavities will be in survivors. This will be informed by future follow-up interval imaging but it is reasonable to assume that though there may be some of regression in the size of the cavities, there will be an increased risk of pneumothorax, hemoptysis, colonization with bacteria including non-tuberculous mycobacteria, fungi and the development of mycetomas in the future.